Statements (68)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:virus
|
| gptkbp:antibody_response |
Ig M and Ig G antibodies
|
| gptkbp:associated_virus |
Canine distemper virus
Rinderpest virus |
| gptkbp:cause |
gptkb:Measles
|
| gptkbp:cell_entry |
CD150 receptor
|
| gptkbp:clinical_trial |
gptkb:Koplik_spots
Ongoing for new vaccines |
| gptkbp:community_health |
Important for prevention strategies
Significant concern |
| gptkbp:complications |
gptkb:Pneumonia
Diarrhea Encephalitis Otitis media |
| gptkbp:diagnosis |
Serological testing
PCR testing |
| gptkbp:diseases |
gptkb:humans
Vaccination campaigns Common in developing countries Common in unvaccinated populations Infects respiratory epithelium |
| gptkbp:epidemiology |
Monitored by health organizations
|
| gptkbp:eradication_status |
Not eradicated
|
| gptkbp:family |
gptkb:Paramyxoviridae
|
| gptkbp:genetic_studies |
gptkb:High
|
| gptkbp:genus |
gptkb:Morbillivirus
|
| gptkbp:global_incidence |
Increased in recent years
|
| gptkbp:global_vaccination_coverage |
Below target in some areas
|
| gptkbp:grooming_needs |
Begins before rash appears
|
| gptkbp:historical_impact |
Significant mortality before vaccination
|
| https://www.w3.org/2000/01/rdf-schema#label |
Measles virus
|
| gptkbp:immunity_duration |
Life-long after infection
|
| gptkbp:immunocompromised_risk |
Higher risk of severe disease
|
| gptkbp:incubation_period |
10 to 14 days
|
| gptkbp:is_compared_to |
Varies by region
|
| gptkbp:is_monitored_by |
Essential for control efforts
Important for outbreak control |
| gptkbp:is_recognized_as |
gptkb:1954
|
| gptkbp:is_vulnerable_to |
gptkb:MMR_vaccine
Measles vaccine Live attenuated vaccine Introduced in 1963 About 97% after two doses First dose at 12-15 months Routine childhood vaccination Second dose at 4-6 years |
| gptkbp:nutritional_value |
Hemagglutinin
Fusion protein |
| gptkbp:originated_in |
Lymphotropic
|
| gptkbp:prevention |
Vaccination
|
| gptkbp:public_awareness |
Critical for vaccination uptake
|
| gptkbp:r0 |
12 to 18
|
| gptkbp:research_focus |
Vaccine development and efficacy
|
| gptkbp:reservoir |
gptkb:None
|
| gptkbp:risk_factor |
Low vaccination rates
|
| gptkbp:scientific_classification |
gptkb:World_Health_Organization
|
| gptkbp:seed_dispersal |
Single-stranded RNA
|
| gptkbp:structure |
Enveloped virus
|
| gptkbp:symptoms |
gptkb:Fever
gptkb:Cough Rash Sore throat Runny nose |
| gptkbp:transmission |
Airborne droplets
|
| gptkbp:treatment |
Supportive care
No specific antiviral treatment |
| gptkbp:bfsParent |
gptkb:Mononegavirales
|
| gptkbp:bfsLayer |
6
|